Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease.
The significance of the selective enrichment in omega-3 essential fatty acids in photoreceptors and synaptic membranes of the nervous system has remained, until recently, incompletely understood. While studying mechanisms of cell survival in neural degeneration, we discovered a docosanoid synthesized from unesterified docosahexaenoic acid (DHA) by a 15-lipoxygenase (15-LOX), which we called neuroprotectin D1 (NPD1; 10R,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15E,19Z hexaenoic acid). This lipid mediator is a docosanoid because it is derived from the 22 carbon (22C) precursor DHA, unlike eicosanoids, which are derived from the 20 carbon (20C) arachidonic acid (AA) family member of essential fatty acids. We discovered that NPD1 is promptly made in response to oxidative stress, as a response to brain ischemia-reperfusion, and in the presence of neurotrophins. NPD1 is neuroprotective in experimental brain damage, in oxidative-stressed retinal pigment epithelial (RPE) cells, and in human brain cells exposed to amyloid-beta (Abeta) peptides. We thus envision NPD1 as a protective sentinel, one of the very first defenses activated when cell homeostasis is threatened by imbalances in normal neural function. We provide here, in three sections, recent experimental examples that highlight the specificity and potency of NPD1 spanning beneficial bioactivity during initiation and early progression of neurodegeneration: (1) during retinal signal phototransduction, (2) during brain ischemia-reperfusion, and (3) in Alzheimer's disease (AD) and stressed human brain cell models of AD. From this experimental evidence, we conclude that DHA-derived NPD1 regulation targets upstream events of brain cell apoptosis, as well as neuro-inflammatory signaling, promoting and maintaining cellular homeostasis, and restoring neural and retinal cell integrity.
Palacios-Pelaez
R
R
Diater Laboratorios, 28918, Leganes, Madrid, Spain. r.palacios@diater.com
Lukiw
Walter J
WJ
Bazan
Nicolas G
NG
D000375:Aging / Q000502:physiology; D000818:Animals; D004041:Dietary Fats / Q000378:metabolism; D018450:Disease Progression; D004281:Docosahexaenoic Acids / Q000378:metabolism*; D015525:Fatty Acids, Omega-3 / Q000378:metabolism*; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000378:metabolism / Q000473:pathology; D055537:Light Signal Transduction / Q000502:physiology; D019636:Neurodegenerative Diseases / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D018696:Neuroprotective Agents / Q000378:metabolism; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology
D004041:Dietary Fats; D015525:Fatty Acids, Omega-3; D018696:Neuroprotective Agents; C487679:protectin D1; D004281:Docosahexaenoic Acids
J Alzheimers Dis. 2010;19(1):341-53
20061649
Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):287-93
18037281
J Immunol. 2004 Mar 1;172(5):2731-8
14978070
Ophthalmic Res. 2001 Jul-Aug;33(4):191-5
11464070
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2903-7
2523075
J Nutr. 2010 Apr;140(4):848-53
20181791
Nutr Neurosci. 2008 Apr;11(2):75-83
18510807
Behav Neurol. 2009;21(1):117-28
19847050
Am J Pathol. 2005 May;166(5):1283-9
15855630
Stroke. 2009 Sep;40(9):3121-6
19542051
J Biol Chem. 2008 Nov 14;283(46):31315-22
18801740
J Neurosci Res. 1999 Aug 15;57(4):479-86
10440897
Acta Neuropathol. 2009 Jul;118(1):103-13
19319544
Curr Opin Clin Nutr Metab Care. 2007 Mar;10(2):136-41
17285000
Trends Neurosci. 2006 May;29(5):263-71
16580739
J Nutr. 2010 Apr;140(4):858-63
20181788
J Alzheimers Dis. 2006 Sep;10(1):59-73
16988483
Neurochem Res. 2004 Jun;29(6):1287-97
15176485
Am J Ophthalmol. 2009 Jul;148(1):83-9.e1
19327745
World Rev Nutr Diet. 2009;99:55-70
19136839
J Clin Invest. 2005 Oct;115(10):2774-83
16151530
Exp Neurol. 2010 Jan;221(1):18-25
19747481
J Am Geriatr Soc. 1977 May;25(5):220-9
856907
J Mol Neurosci. 2001 Apr-Jun;16(2-3):159-65; discussion 215-21
11478370
Mol Neurobiol. 2010 Aug;42(1):10-6
20414817
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13158-63
17670935
J Alzheimers Dis. 2010;19(2):489-502
20110596
Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):205-11
19520558
Mol Vis. 2009 Jun 13;15:1185-93
19536303
Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):251-61
18060754
Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):233-8
18060755
Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):213-21
19523795
N Engl J Med. 2010 Jan 28;362(4):329-44
20107219
Invest Ophthalmol Vis Sci. 2007 Nov;48(11):4866-81; biography 4864-5
17962433
J Nutr. 2007 Apr;137(4):855-9
17374644
Br J Ophthalmol. 2009 Sep;93(9):1241-6
19508997
J Alzheimers Dis. 2010;21(1):1-14
20182045
J Lipid Res. 2009 Apr;50 Suppl:S400-5
19018037
Curr Pharm Des. 2009;15(36):4186-90
20041820
Neuroscience. 1999;94(1):305-14
10613520
Biochim Biophys Acta. 2007 Aug;1768(8):1976-90
17433250
Ann N Y Acad Sci. 2005 Aug;1053:137-47
16179516
Drug News Perspect. 2007 Oct;20(8):501-9
18080037
Curr Opin Clin Nutr Metab Care. 2010 Jan;13(1):28-33
19841580
Indian J Pediatr. 2005 Mar;72(3):239-42
15812120
Neuropharmacology. 2010 Sep-Oct;59(4-5):243-67
20167227
Mol Cell Biochem. 1992 Oct 21;116(1-2):19-25
1480148
Insight. 2008 Oct-Dec;33(4):20-5; quiz 26-7
19227095
Mol Neurobiol. 2006 Dec;34(3):181-92
17308351
J Neurosci Res. 1998 Sep 1;53(5):583-92
9726429
Biochim Biophys Acta. 2010 Aug;1801(8):924-9
20176130
J Neurochem. 1998 Jun;70(6):2484-91
9603213
Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):85-9
19804838
Gerontology. 2010;56(1):3-14
19752507
J Med Food. 2007 Jun;10(2):225-31
17651056
J Neurosci Res. 2002 Nov 1;70(3):462-73
12391607
Biochem Soc Trans. 2006 Dec;34(Pt 6):1277-82
17073801
J Biol Chem. 2003 Oct 31;278(44):43807-17
12923200
Blood Press. 1995 May;4(3):177-86
7670652
Annu Rev Cell Dev Biol. 2005;21:633-57
16212510
J Invest Surg. 2005 Nov-Dec;18(6):335-50
16319055
J Nutr. 2010 Apr;140(4):869-74
20181786